RxDoctor Payments Data

Razan Alif, MD

Internal Medicine · Wellington, FLNPI 1407389323

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Novo Nordisk at 33.1% of the total. That places this record below the midpoint for internal medicine clinicians in FL, where the typical reported total is $316.

$197in general payments, 2019–2025

Across 11 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$65
  • Abbott$43
  • Boehringer Ingelheim$39
  • Pfizer$23
  • Lilly USA, LLC$15
  • Boston Scientific$13

What the payments were for

  • Food & beverage$197100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$197 in reported general payments places this provider in the 40th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$100,441
Medicare patients
243
Services billed
1,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$71,297
OzempicSemaglutide47$56,850
MounjaroTirzepatide33$40,738
XareltoRivaroxaban37$39,523
JardianceEmpagliflozin33$23,974
LinzessLinaclotide16$8,571
SymbicortBudesonide/Formoterol Fumarate13$2,850
SynthroidLevothyroxine Sodium45$2,684
Rosuvastatin Calcium190$2,615
Levothyroxine Sodium210$2,466
Atorvastatin Calcium282$2,154
Losartan Potassium183$1,902
Celecoxib27$1,585
Omeprazole126$1,423
Gabapentin77$1,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$71,29752 claims
Novo NordiskOzempic$65$56,85047 claims
Lilly USA, LLCMounjaro$15$40,73833 claims
Boehringer IngelheimJardiance$39$23,97433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Wellington

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →